ArticleLeukemia & lymphoma2022

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.

Jorge M Ramos Perez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.